← Insights
Weekly digest
Weekly digest, Sep 28 to Oct 4, 2026: 276 new earnings analyses
Published Oct 4, 2026
276 new earnings analyses (including ASPI, ASPS, ASST) and 4 market briefs from Sep 28 to Oct 4, 2026.
This week: 276 new earnings analyses and 4 market briefs were published from Sep 28 to Oct 4, 2026. Everything below is taken from those pieces; nothing here is new reporting.
New earnings analyses
| Report | Revenue | Revenue vs. a year earlier | Diluted EPS | EPS vs. a year earlier |
|---|---|---|---|---|
| ASPI Q2 2026 | $5.1M | +327.6% | $-0.27 | n/a |
| ASPS Q2 2026 | $51M | +17.0% | $-0.05 | -103.4% |
| ASST Q2 2026 | $2.9M | +94.6% | $-3.77 | n/a |
| ASBP Q2 2026 | $63K | n/a | $-1.22 | n/a |
| ASRV Q2 2026 | $16M | +9.8% | $0.16 | n/a |
| ASMB Q2 2026 | $13M | +38.9% | $-0.20 | n/a |
| ASO Q2 2026 | $1.6B | +3.0% | $2.17 | +17.3% |
| ASLE Q2 2026 | $71M | -33.9% | $-0.12 | -166.7% |
| ASML Q2 2026 | EUR 9.3B | +21.3% | EUR 7.58 | +28.5% |
| ASND Q2 2026 | EUR 339M | +114.7% | EUR 2.83 | n/a |
| ARXS Q2 2026 | $501M | +25.0% | $-0.01 | n/a |
| ARVN Q2 2026 | $250M | n/a | $2.58 | n/a |
| ARWR Q3 2026 | $75M | +171.0% | $-1.36 | n/a |
| ARTL Q2 2026 | n/a | n/a | $-0.89 | n/a |
| ARRY Q2 2026 | $342M | -5.6% | $0.05 | -73.7% |
| ARTW Q2 2026 | $7.9M | +23.9% | $0.03 | -89.7% |
| ARTNA Q2 2026 | $31M | +7.4% | $0.64 | +4.9% |
| ARTV Q2 2026 | $0K | n/a | $-0.63 | n/a |
| ARKR Q3 2026 | $41M | -6.5% | $-0.10 | n/a |
| ARHS Q2 2026 | $385M | +7.4% | $0.28 | +12.0% |
| ARQ Q2 2026 | $30M | +4.5% | $-0.02 | n/a |
| ARQT Q2 2026 | $130M | +59.3% | $0.11 | n/a |
| ARKO Q2 2026 | $2.3B | +17.4% | $0.04 | -75.0% |
| AROW Q2 2026 | $44M | +10.1% | $0.66 | +1.5% |
| ARDX Q2 2026 | $121M | +23.8% | $-0.07 | n/a |
| ARGX H1 (Interim) 2026 | $2.9B | +60.8% | $13.00 | +105.7% |
| ARCC Q2 2026 | $768M | +3.1% | $0.24 | -53.8% |
| ARCT Q2 2026 | $3.0M | -89.5% | $-0.84 | n/a |
| ARCB Q2 2026 | $1.2B | +15.9% | $-0.62 | -155.4% |
| ARBB H1 (Interim) 2026 | MYR 150M | +82.0% | MYR -8.31 | +46.7% |
| AQST Q2 2026 | $14M | +38.2% | $-0.18 | n/a |
| AQB Q2 2026 | $0K | n/a | $-0.32 | -63.2% |
| APYX Q2 2026 | $14M | +22.1% | $-0.07 | n/a |
| AQMS Q2 2026 | $0K | n/a | $-1.31 | -82.4% |
| APWC Q2 2026 | $137M | +7.7% | $0.01 | -66.7% |
| APVO Q2 2026 | n/a | n/a | $-5.31 | n/a |
| APPS Full Year 2026 | $565M | +15.2% | $-0.33 | n/a |
| APPN Q2 2026 | $203M | +19.1% | $-0.16 | n/a |
| APOG Full Year 2026 | $1.4B | +3.2% | $2.52 | -35.2% |
| APPF Q2 2026 | $281M | +19.3% | $1.17 | +18.2% |
Biggest swings in revenue
Year-over-year revenue change as reported in each analysis, among this week's reports.
Fastest growth
- AIIO H1 (Interim) 2026: revenue +9527.8%
- ALGS Q2 2026: revenue +2778.6%
- ACIU H1 (Interim) 2026: revenue +607.0%
Slowest growth or decline
- AIMD Q2 2026: revenue -96.7%
- ABUS Q2 2026: revenue -90.6%
- ARCT Q2 2026: revenue -89.5%
What the analyses found
- ASPI Q2 2026 (Revenue $5.1M (+327.6%) · EPS $-0.27): Revenue rose to $5.1M on acquired radiopharmacies and Renergen LNG, but excluding convertible-note revaluations the loss widened to $30.1M from $11.2M; enriched-isotope sales have yet to start.
- ASPS Q2 2026 (Revenue $51M (+17.0%) · EPS $-0.05 (-103.4%)): Altisource grew Q2 2026 service revenue 19% to $48.7M on new customer wins, but thinner-margin Lenders One resale business cut gross margin to 26% and operating income fell 65% to $1.1M, for a $(0.05) per-share loss.
- ASST Q2 2026 (Revenue $2.9M (+94.6%) · EPS $-3.77): Strive lost $257.6M in Q2 2026, almost all from a $228.0M bitcoin markdown, while growing its holdings to 19,864 BTC funded by stock and 13%-dividend SATA preferred sales; revenue was $2.9M.
- ASBP Q2 2026 (Revenue $63K · EPS $-1.22): Aspire's Q2 2026 revenue was $63,104 against $2.65M of operating costs; a one-off $1.35M lawsuit write-off hid a tripled operating loss, before an August pivot into a $30M auto-parts acquisition.
- ASRV Q2 2026 (Net interest income $11M (+9.1%) · NIM 3.34% · EPS $0.16): AmeriServ earned $2.74M ($0.16/share) vs a $0.28M loss a year ago as its net interest margin widened to 3.34% and last year's $3.1M problem-loan provision did not recur.
- ASMB Q2 2026 (Revenue $13M (+38.9%) · EPS $-0.20): Assembly Biosciences' Q2 loss narrowed to $3.9M ($0.20/share) mostly on a one-time $5.1M Gilead revenue catch-up, while a $115M May offering lifted cash to $320.4M and runway into late 2028 ahead of 6250 Phase 2 starts.
- ASO Q2 2026 (Revenue $1.6B (+3.0%) · EPS $2.17 (+17.3%)): Academy's Q2 sales rose 3.0% on new stores while comparable sales fell 0.4%; an $83.7M tariff refund lifted operating margin to 15.0%, but most of it was paid away below the line and EPS growth to $2.17 leaned on a 6.1% smaller share count.
- ASLE Q2 2026 (Revenue $71M (-33.9%) · EPS $-0.12 (-166.7%)): AerSale's Q2 2026 revenue fell 33.9% to $70.9 million as whole-engine sales dried up against a strong prior-year quarter, and near-zero margins at its restarted Millington MRO hangar pushed the company to a $5.6 million net loss.
- ASML Q2 2026 (Revenue EUR 9.3B (+21.3%) · EPS EUR 7.58 (+28.5%)): ASML's Q2 2026 sales rose 21.3% to €9.33 billion and net income 27.4% to €2.92 billion on EUV and service growth; it raised 2026 sales guidance to €43–45 billion, though first-half free cash flow was negative.
- ASND Q2 2026 (Revenue EUR 339M (+114.7%) · EPS EUR 2.83): Ascendis more than doubled revenue to €339M on YORVIPATH's €252M; a €158M voucher sale lifted net profit to €207M, though operating profit without it was about €62M.
- ARXS Q2 2026 (Revenue $501M (+25.0%) · EPS $-0.01): Arxis grew revenue 25% (21% organic) to $500.7M in its first quarter as a public company, but a $107M IPO-related stock-compensation charge cut operating margin to 6.5% and produced a $4.9M net loss.
- ARVN Q2 2026 (Revenue $250M · EPS $2.58): Arvinas posted a $169.4M Q2 profit ($2.58/share) on $249.7M revenue, but $238.9M of that came from one-time VEPPANU approval and Rigel-licensing accounting; underlying operating loss was about $66M and cash fell to $567.9M.
Plus 264 more on the latest reports page.
Market briefs this week
- Fed stress tests, SEC rules, Accenture results – Market Brief, Oct 1, 2026: The Fed finalized stress-test changes, the SEC proposed wider retail access to private markets, and Accenture and McCormick filed quarterly results.
- Boeing wins Navy jet deal; Jabil posts results – Market Brief, Sep 30, 2026: Boeing shares rose after the U.S. Navy picked it for a next-generation fighter, Jabil filed quarterly results, and the SEC charged WhatsApp investment scams.
- US-China cut tariffs; SEC settles Zoe case – Market Brief, Sep 29, 2026: Washington and Beijing agreed to lower tariffs on $60 billion of goods, the SEC settled charges with adviser Zoe Financial, and TSMC eyes a second US hub.
- Nvidia's $150B buyback, US-China tariff cuts – Market Brief, Sep 28, 2026: Nvidia announces a $150 billion share repurchase plan, the US and China agree to cut tariffs on $60 billion of goods, and the 10-year Treasury yield hits a 19-…
Assembled automatically each week from this site's own published analyses and briefs. Figures are as stated in each linked report. For information only; not investment advice.
Related analyses
- ASP Isotopes Inc. (ASPI) · Q2 2026Revenue $5.1M (+327.6%) · EPS $-0.27
Revenue rose to $5.1M on acquired radiopharmacies and Renergen LNG, but excluding convertible-note revaluations the loss widened to $30.1M from $11.2M; enriched-isotope sales have yet to start.
- Altisource Portfolio Solutions S.A. (ASPS) · Q2 2026Revenue $51M (+17.0%) · EPS $-0.05 (-103.4%)
Altisource grew Q2 2026 service revenue 19% to $48.7M on new customer wins, but thinner-margin Lenders One resale business cut gross margin to 26% and operating income fell 65% to $1.1M, for a $(0.05) per-share loss.
- Strive, Inc. (ASST) · Q2 2026Revenue $2.9M (+94.6%) · EPS $-3.77
Strive lost $257.6M in Q2 2026, almost all from a $228.0M bitcoin markdown, while growing its holdings to 19,864 BTC funded by stock and 13%-dividend SATA preferred sales; revenue was $2.9M.
- Aspire-Lakewood Holdings, Inc. (ASBP) · Q2 2026Revenue $63K · EPS $-1.22
Aspire's Q2 2026 revenue was $63,104 against $2.65M of operating costs; a one-off $1.35M lawsuit write-off hid a tripled operating loss, before an August pivot into a $30M auto-parts acquisition.
For information only; not investment advice.